Table 2 Demographic and clinical characteristics of MDD patients stratified by whether they experienced remission or not
From: RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
Characteristic | Remission (n = 9) | Non-remission (n = 75) | F or χ2 | p |
|---|---|---|---|---|
Demographic characteristics | ||||
  Age (years) | 15.00 ± 1.32 | 14.45 ± 1.47 | 0.249 | 0.291 |
  Sex (Male/Female) | 3/6 | 11/64 | 2.016 | 0.168 |
  Level of education (Junior/Senior) | 5/4 | 43/32 | 0.01 | 1 |
Clinical characteristics | ||||
  CCSQ total score | 146.78 ± 39.28 | 137.41 ± 39.81 | 0.004 | 0.506 |
  Peer bullying | 30.56 ± 15.44 | 28.34 ± 11.99 | 1.798 | 0.613 |
  Childhood abuse and neglect | 68.00 ± 20.72 | 63.98 ± 22.23 | 0.451 | 0.607 |
  Adverse childhood experience | 48.22 ± 13.07 | 45.10 ± 13.35 | 0.000 | 0.508 |
  Baseline BDI score | 30.78 ± 6.76 | 34.88 ± 9.03 | 0.213 | 0.191 |
  Antidepressant dosea (mg) | 36.94 ± 11.94 | 40.15 ± 16.61 | 1.354 | 0.577 |
  RPS6KA5 methylation percentage | 7.39 ± 1.99 | 5.19 ± 2.99 | 2.825 | 0.035 |